HIV medications: Difference between revisions
From IDWiki
(→) |
(Added link for crushability chart) |
||
(12 intermediate revisions by the same user not shown) | |||
Line 1: | Line 1: | ||
== |
==Classes== |
||
{| class="wikitable" |
{| class="wikitable" |
||
! |
!Class |
||
! |
!Examples |
||
!Mechanism of Action |
|||
! Description |
|||
!Adverse Effects |
|||
|- |
|- |
||
| |
|Nucleoside reverse-transcriptase inhibitor (NRTI) |
||
| |
|[[tenofovir]], [[emtricitabine]], [[abacavir]] |
||
| |
|Nucleoside/nucleotide analogues that get incorporated into viral DNA by reverse transcriptase, causing missense or non-sense mutations. The backbone of HIV treatments, with a high barrier to resistance. |
||
⚫ | |||
|- |
|- |
||
|Non-nucleoside reverse-transcriptase inhibitor (NNRTI) |
|||
| Non-NRTI |
|||
| |
|[[efavirenz]] |
||
| |
|Actively inhibit reverse transcriptase at its active site. Resistance develops with a single point mutation. |
||
⚫ | |||
|- |
|- |
||
| |
|Protease inhibitor (PI) |
||
| |
|[[dirunavir]] |
||
| |
|Inhibits protease, which is required for processing proteins in the creation of the virion. |
||
|Metabolic syndrome |
|||
|- |
|- |
||
| |
|Integrase strand transfer inhibitor (INSTI) |
||
| |
|[[raltegravir]], [[dolutegravir]], [[bictegravir]] |
||
| |
|||
| Extremely potent with few side effects. Take separate from PPIs etc. |
|||
|Generally very well-tolerated; may cause weight gain and diabetes |
|||
|- |
|- |
||
| |
|Fusion inhibitor |
||
| |
|||
| |
| |
||
| |
| |
||
|- |
|- |
||
| |
|CCR5 entry inhibitor |
||
|[[maraviroc]] |
|||
⚫ | |||
⚫ | |||
| |
| |
||
|- |
|- |
||
| |
|CD4-mAb |
||
| |
|[[ibalizumab]] |
||
| |
|||
⚫ | |||
| |
|||
|} |
|} |
||
== |
==Specific Medications== |
||
{| class="wikitable sortable" |
{| class="wikitable sortable" |
||
⚫ | |||
! |
!Medication!!Abbr |
||
! AKA |
|||
⚫ | |||
⚫ | |||
⚫ | |||
|- |
|- |
||
| rowspan="6" |NRTI |
|||
| |
|[[lamivudine]]||3TC |
||
| 3TC |
|||
| NRTI |
|||
| |
| |
||
|- |
|- |
||
| |
|[[emtricitabine]]||FTC |
||
| FTC |
|||
| NRTI |
|||
| |
| |
||
|- |
|- |
||
| |
|[[tenofovir disoproxol fumarate]]||TDF |
||
| TDF |
|||
| NRTI |
|||
| |
| |
||
|- |
|- |
||
| |
|[[tenofovir alafenamide]]||TAF |
||
⚫ | |||
| TAF |
|||
| NRTI |
|||
⚫ | |||
|- |
|- |
||
| |
|[[zidovudine]]||AZT |
||
| AZT |
|||
| NRTI |
|||
| |
| |
||
|- |
|- |
||
| |
|[[abacavir]]||ABC |
||
⚫ | |||
| ABC |
|||
| NRTI |
|||
⚫ | |||
|- |
|- |
||
| rowspan="4" |NNRTI |
|||
| [[efavirenz]] |
|||
| |
|[[efavirenz]]||EFZ |
||
| NNRTI |
|||
| |
| |
||
|- |
|- |
||
| |
|[[nevirapine]]||NVP |
||
| |
|||
| RPV |
|||
|- |
|||
| NNRTI |
|||
|[[rilpivirine]]||RPV |
|||
| |
|Take with meal, not with PPI. |
||
|- |
|- |
||
| |
|[[doravirine]]||DOR |
||
| DOR |
|||
| NNRTI |
|||
| |
| |
||
|- |
|- |
||
| rowspan="3" |PI |
|||
| |
|[[lopinavir/ritonavir]]||LPV/r |
||
| LPV/r |
|||
⚫ | |||
| PI |
|||
⚫ | |||
|- |
|- |
||
| |
|[[darunivir]]||DRV |
||
| DRV |
|||
| PI |
|||
| |
| |
||
|- |
|- |
||
| |
|[[ritonavir]]||RTV |
||
| |
|||
| DTG |
|||
|- |
|||
| INSTI |
|||
| rowspan="5" |INSTI |
|||
⚫ | |||
|[[dolutegravir]]||DTG |
|||
⚫ | |||
|- |
|- |
||
| |
|[[elvitegravir/cobicistat]]||EVG/c |
||
⚫ | |||
| EVG/c |
|||
| INSTI |
|||
⚫ | |||
|- |
|- |
||
| |
|[[raltegravir]]||RAL |
||
⚫ | |||
| RAL |
|||
| INSTI |
|||
⚫ | |||
|- |
|- |
||
| |
|[[bictegravir]]||BIC |
||
| BIC |
|||
| INSTI |
|||
| |
| |
||
|- |
|- |
||
| |
|[[cabotegravir]]||CAB |
||
⚫ | |||
| CAB |
|||
| INSTI |
|||
⚫ | |||
|- |
|- |
||
⚫ | |||
| |
| |
||
⚫ | |||
⚫ | |||
| |
|CD4-receptor antibody. |
||
|} |
|} |
||
== |
==Single-Tablet Regimens== |
||
{| class="wikitable sortable" |
{| class="wikitable sortable" |
||
! |
!Brand name |
||
! |
!NRTIs |
||
! |
!Non-NRTI |
||
! |
!First-line? |
||
! |
!Notes |
||
|- |
|- |
||
| |
|Atripla |
||
| |
|[[tenofovir disoproxil fumarate]] / [[emtricitabine]] |
||
| |
|[[efavirenz]] (NNRTI) |
||
| |
|No |
||
| |
|Older regimen. Neuropsychiatric symptoms, possibly including suicide. No dose adjustment with [[rifampin]]. |
||
|- |
|- |
||
| |
|Biktarvy |
||
| |
|[[tenofovir alafenamide]] / [[emtricitabine]] |
||
| |
|[[bictegravir]] (INI) |
||
| |
|Yes |
||
| |
| |
||
|- |
|- |
||
| |
|Complera |
||
| |
|[[tenofovir disoproxil fumarate]] / [[emtricitabine]] |
||
| |
|[[rilpivirine]] (NNRTI) |
||
| |
|No |
||
| |
|Avoid with viral loads (>100,000) or low CD4 (<200). Pill must be taken with food (>400kcal) and without PPIs. |
||
|- |
|- |
||
| |
|Delstrigo |
||
| |
|[[tenofovir disoproxil fumarate]] / [[lamivudine]] |
||
| |
|[[doravirine]] (NNRTI) |
||
| |
|No |
||
| |
| |
||
|- |
|- |
||
| |
|Dovato |
||
| |
|[[emtricitabine]] |
||
| |
|[[dolutegravir]] (INI) |
||
| |
|Yes |
||
| |
|Two-medication regimen |
||
|- |
|- |
||
| |
|Genvoya |
||
| |
|[[tenofovir alafenamide]] / [[emtricitabine]] |
||
| |
|[[elvitegravir]]/[[cobicistat]] (INI) |
||
| |
|No |
||
| |
|See Stribild, above. |
||
|- |
|- |
||
| |
|Odefsey |
||
| |
|[[tenofovir alafenamide]] / [[emtricitabine]] |
||
| |
|[[rilpivirine]] (NNRTI) |
||
| |
|No |
||
| |
| |
||
|- |
|- |
||
| |
|Stribild |
||
| |
|[[tenofovir disoproxil fumarate]] / [[emtricitabine]] |
||
| |
|[[elvitegravir]]/[[cobicistat]] (INI) |
||
| |
|No |
||
| |
|Includes a P450 inhibitor to boost elvitegravir levels, with resultant drug-drug interactions. Avoid if CrCl <70. |
||
|- |
|- |
||
| |
|Symfi |
||
| |
|[[tenofovir disoproxil fumarate]] / [[emtricitabine]] |
||
| |
|[[efavirenz]] (NNRTI) |
||
| |
|No |
||
| |
| |
||
|- |
|- |
||
| |
|Symtuza |
||
| |
|[[tenofovir alafenamide]] / [[emtricitabine]] |
||
| |
|[[darunavir]]/[[cobicistat]] (PI) |
||
| |
|No |
||
| |
| |
||
|- |
|- |
||
| |
|Triumeq |
||
| |
|[[abacavir]] / [[lamivudine]] |
||
| |
|[[dolutegravir]] (INI) |
||
| |
|Yes |
||
| |
|Highest barrier to resistance. Need to test for HLA-B5701 allele before starting. Avoid in hepatitis B coinfection. |
||
|} |
|} |
||
== |
== Crushing Medications == |
||
* See https://www.hivclinic.ca/main/drugs_extra_files/Crushing%20and%20Liquid%20ARV%20Formulations.pdf |
|||
* Hepatitis B: Avoid Triumeq; use TDF/FTC-based regimen instead |
|||
* CKD: Avoid Stribild in CrCl <70 |
|||
== |
==Further Reading== |
||
* |
*Andany N and Gold WL. [https://doi.org/10.1503/cmaj.151412 Five things to know about single-tablet antiretroviral treatment (once daily)]. ''CMAJ''. 2016;188(13)971. |
||
* |
*Gandhi M and Gandhi RT. [https://doi.org/10.1056/NEJMct1215532 Single-Pill Combination Regimens for Treatment of HIV-1 Infection]. ''N Engl J Med''. 2014;371:248-259. |
||
[[Category:HIV]] |
[[Category:HIV]] |
Latest revision as of 12:32, 25 January 2024
Classes
Class | Examples | Mechanism of Action | Adverse Effects |
---|---|---|---|
Nucleoside reverse-transcriptase inhibitor (NRTI) | tenofovir, emtricitabine, abacavir | Nucleoside/nucleotide analogues that get incorporated into viral DNA by reverse transcriptase, causing missense or non-sense mutations. The backbone of HIV treatments, with a high barrier to resistance. | |
Non-nucleoside reverse-transcriptase inhibitor (NNRTI) | efavirenz | Actively inhibit reverse transcriptase at its active site. Resistance develops with a single point mutation. | |
Protease inhibitor (PI) | dirunavir | Inhibits protease, which is required for processing proteins in the creation of the virion. | Metabolic syndrome |
Integrase strand transfer inhibitor (INSTI) | raltegravir, dolutegravir, bictegravir | Generally very well-tolerated; may cause weight gain and diabetes | |
Fusion inhibitor | |||
CCR5 entry inhibitor | maraviroc | Blocks entry of HIV into CD4 cells. | |
CD4-mAb | ibalizumab |
Specific Medications
Class | Medication | Abbr | Notes |
---|---|---|---|
NRTI | lamivudine | 3TC | |
emtricitabine | FTC | ||
tenofovir disoproxol fumarate | TDF | ||
tenofovir alafenamide | TAF | Fewer renal and bone effects. | |
zidovudine | AZT | ||
abacavir | ABC | Need to check HLA-B*5701 before starting therapy. | |
NNRTI | efavirenz | EFZ | |
nevirapine | NVP | ||
rilpivirine | RPV | Take with meal, not with PPI. | |
doravirine | DOR | ||
PI | lopinavir/ritonavir | LPV/r | GI side effects. |
darunivir | DRV | ||
ritonavir | RTV | ||
INSTI | dolutegravir | DTG | Increases metformin levels. Avoid in pregnancy. |
elvitegravir/cobicistat | EVG/c | Requires booster that has drug interaction. | |
raltegravir | RAL | First INSTI. BID dosing. Only INSTI that can be used in pregnancy. | |
bictegravir | BIC | ||
cabotegravir | CAB | Long-acting injectable available. | |
ibalizumab | CD4-receptor antibody. |
Single-Tablet Regimens
Brand name | NRTIs | Non-NRTI | First-line? | Notes |
---|---|---|---|---|
Atripla | tenofovir disoproxil fumarate / emtricitabine | efavirenz (NNRTI) | No | Older regimen. Neuropsychiatric symptoms, possibly including suicide. No dose adjustment with rifampin. |
Biktarvy | tenofovir alafenamide / emtricitabine | bictegravir (INI) | Yes | |
Complera | tenofovir disoproxil fumarate / emtricitabine | rilpivirine (NNRTI) | No | Avoid with viral loads (>100,000) or low CD4 (<200). Pill must be taken with food (>400kcal) and without PPIs. |
Delstrigo | tenofovir disoproxil fumarate / lamivudine | doravirine (NNRTI) | No | |
Dovato | emtricitabine | dolutegravir (INI) | Yes | Two-medication regimen |
Genvoya | tenofovir alafenamide / emtricitabine | elvitegravir/cobicistat (INI) | No | See Stribild, above. |
Odefsey | tenofovir alafenamide / emtricitabine | rilpivirine (NNRTI) | No | |
Stribild | tenofovir disoproxil fumarate / emtricitabine | elvitegravir/cobicistat (INI) | No | Includes a P450 inhibitor to boost elvitegravir levels, with resultant drug-drug interactions. Avoid if CrCl <70. |
Symfi | tenofovir disoproxil fumarate / emtricitabine | efavirenz (NNRTI) | No | |
Symtuza | tenofovir alafenamide / emtricitabine | darunavir/cobicistat (PI) | No | |
Triumeq | abacavir / lamivudine | dolutegravir (INI) | Yes | Highest barrier to resistance. Need to test for HLA-B5701 allele before starting. Avoid in hepatitis B coinfection. |
Crushing Medications
- See https://www.hivclinic.ca/main/drugs_extra_files/Crushing%20and%20Liquid%20ARV%20Formulations.pdf
Further Reading
- Andany N and Gold WL. Five things to know about single-tablet antiretroviral treatment (once daily). CMAJ. 2016;188(13)971.
- Gandhi M and Gandhi RT. Single-Pill Combination Regimens for Treatment of HIV-1 Infection. N Engl J Med. 2014;371:248-259.